ARQT
Price
$26.73
Change
+$0.68 (+2.61%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
3.19B
48 days until earnings call
Intraday BUY SELL Signals
CLDX
Price
$26.31
Change
+$0.38 (+1.47%)
Updated
Jan 14, 04:59 PM (EDT)
Capitalization
1.72B
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs CLDX

Header iconARQT vs CLDX Comparison
Open Charts ARQT vs CLDXBanner chart's image
Arcutis Biotherapeutics
Price$26.73
Change+$0.68 (+2.61%)
Volume$33.95K
Capitalization3.19B
Celldex Therapeutics
Price$26.31
Change+$0.38 (+1.47%)
Volume$20.79K
Capitalization1.72B
ARQT vs CLDX Comparison Chart in %
View a ticker or compare two or three
VS
ARQT vs. CLDX commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and CLDX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ARQT: $26.05 vs. CLDX: $25.93)
Brand notoriety: ARQT and CLDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 93% vs. CLDX: 108%
Market capitalization -- ARQT: $3.19B vs. CLDX: $1.72B
ARQT [@Biotechnology] is valued at $3.19B. CLDX’s [@Biotechnology] market capitalization is $1.72B. The market cap for tickers in the [@Biotechnology] industry ranges from $115.36B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileCLDX’s FA Score has 0 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • CLDX’s FA Score: 0 green, 5 red.
According to our system of comparison, ARQT is a better buy in the long-term than CLDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 4 TA indicator(s) are bullish while CLDX’s TA Score has 2 bullish TA indicator(s).

  • ARQT’s TA Score: 4 bullish, 5 bearish.
  • CLDX’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ARQT is a better buy in the short-term than CLDX.

Price Growth

ARQT (@Biotechnology) experienced а -10.85% price change this week, while CLDX (@Biotechnology) price change was -1.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.47%. For the same industry, the average monthly price growth was +3.44%, and the average quarterly price growth was +44.89%.

Reported Earning Dates

ARQT is expected to report earnings on Mar 03, 2026.

CLDX is expected to report earnings on Mar 02, 2026.

Industries' Descriptions

@Biotechnology (+0.47% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARQT($3.19B) has a higher market cap than CLDX($1.72B). CLDX YTD gains are higher at: -4.529 vs. ARQT (-10.296). ARQT has higher annual earnings (EBITDA): -23.61M vs. CLDX (-252.86M). CLDX has more cash in the bank: 583M vs. ARQT (191M). CLDX has less debt than ARQT: CLDX (2.62M) vs ARQT (114M). ARQT has higher revenues than CLDX: ARQT (318M) vs CLDX (2.6M).
ARQTCLDXARQT / CLDX
Capitalization3.19B1.72B185%
EBITDA-23.61M-252.86M9%
Gain YTD-10.296-4.529227%
P/E RatioN/AN/A-
Revenue318M2.6M12,235%
Total Cash191M583M33%
Total Debt114M2.62M4,349%
FUNDAMENTALS RATINGS
ARQT vs CLDX: Fundamental Ratings
ARQT
CLDX
OUTLOOK RATING
1..100
537
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
10083
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
3959
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a42

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARQT's Valuation (62) in the null industry is in the same range as CLDX (70) in the Biotechnology industry. This means that ARQT’s stock grew similarly to CLDX’s over the last 12 months.

CLDX's Profit vs Risk Rating (83) in the Biotechnology industry is in the same range as ARQT (100) in the null industry. This means that CLDX’s stock grew similarly to ARQT’s over the last 12 months.

ARQT's SMR Rating (96) in the null industry is in the same range as CLDX (97) in the Biotechnology industry. This means that ARQT’s stock grew similarly to CLDX’s over the last 12 months.

ARQT's Price Growth Rating (39) in the null industry is in the same range as CLDX (59) in the Biotechnology industry. This means that ARQT’s stock grew similarly to CLDX’s over the last 12 months.

ARQT's P/E Growth Rating (100) in the null industry is in the same range as CLDX (100) in the Biotechnology industry. This means that ARQT’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARQTCLDX
RSI
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 7 days ago
85%
Bullish Trend 8 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 10 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ARQT
Daily Signal:
Gain/Loss:
CLDX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSGFX10.410.04
+0.39%
Victory RS Select Growth C
FEMSX26.16N/A
N/A
Fidelity Series Emerging Markets Opps
FIRIX10.77N/A
N/A
Fidelity Advisor Intl Real Estate I
JSGRX29.59-0.01
-0.03%
JHancock U.S. Growth R2
BIRKX24.01-0.07
-0.29%
BlackRock Sust Awr Advtg Lg Cp Cr K

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
-2.73%
IDYA - ARQT
46%
Loosely correlated
-4.75%
XNCR - ARQT
42%
Loosely correlated
-1.62%
XENE - ARQT
41%
Loosely correlated
-2.11%
NUVL - ARQT
41%
Loosely correlated
+2.03%
CLDX - ARQT
40%
Loosely correlated
+1.01%
More

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with XNCR. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
+1.01%
XNCR - CLDX
56%
Loosely correlated
-1.62%
KURA - CLDX
55%
Loosely correlated
+0.44%
VRDN - CLDX
54%
Loosely correlated
-1.78%
NUVL - CLDX
52%
Loosely correlated
+2.03%
APGE - CLDX
51%
Loosely correlated
+1.74%
More